Financial Performance - The company achieved operating revenue of RMB 568.98 million in Q1 2022, representing a year-on-year growth of 10.27%[7] - Net profit attributable to shareholders was RMB 12.51 million, with a year-on-year decrease of 40.99% due to a one-time special gain from a subsidiary becoming an associate last year[7] - The company’s weighted average return on equity was 2.21%, a decrease of 2.36 percentage points compared to the previous year[14] - Net profit for Q1 2022 was RMB 1.53 billion, down 35.56% from RMB 2.38 billion in Q1 2021[28] - Operating profit for Q1 2022 was RMB 1.99 billion, a decrease of 33.38% compared to RMB 2.99 billion in Q1 2021[28] - The company reported a total comprehensive income of RMB 1.49 billion for Q1 2022, down from RMB 2.32 billion in Q1 2021[29] Revenue Breakdown - The pharmaceutical industry segment generated sales revenue of RMB 69.28 million, with a year-on-year increase of 7.14%[7] - The pharmaceutical commerce segment reported sales revenue of RMB 499.70 million, reflecting a year-on-year growth of 10.72%[7] - The pharmaceutical industry sales revenue reached RMB 6.928 billion, an increase of 7.14% year-on-year; sales revenue for 60 key products was RMB 4.033 billion, up 15.05% year-on-year[12] - The pharmaceutical distribution business achieved sales revenue of RMB 50.157 billion, an increase of 11.39% year-on-year; the retail business saw sales revenue of RMB 1.737 billion, a decrease of 9.39% year-on-year[13] - The company’s non-pharmaceutical business, including medical devices and health products, achieved sales revenue of RMB 6.698 billion, a year-on-year growth of approximately 35%[13] Research and Development - The company invested RMB 4.48 million in R&D expenses, marking a year-on-year increase of 7.95%[8] - The research and development team increased personnel from 613 at the beginning of 2021 to 838 by year-end, a growth of 37%[12] - Research and development expenses increased to RMB 447.50 million in Q1 2022, up from RMB 414.54 million in Q1 2021, reflecting a focus on innovation[27] - The company added 6 varieties (7 specifications) that passed the consistency evaluation of generic drugs, bringing the total to 43 varieties (62 specifications) approved, ranking among the industry leaders[13] Cash Flow and Financing - The company experienced an operating cash outflow of RMB 24.90 million due to the impact of the pandemic[8] - The company’s cash flow from operating activities was negative at RMB -2.490 billion, indicating a significant cash outflow during the reporting period[14] - Total cash inflow from financing activities in Q1 2022 was 34,746,768,726.73, a substantial increase from 17,733,043,737.07 in Q1 2021, reflecting strong financing efforts[33] - The net cash flow from financing activities for Q1 2022 was 17,594,227,843.63, a significant rise from 2,924,513,473.88 in Q1 2021, indicating improved capital raising[33] - Cash and cash equivalents at the end of Q1 2022 totaled 34,611,200,668.81, up from 19,381,758,246.06 in Q1 2021, demonstrating strong liquidity position[33] Assets and Liabilities - The company’s total assets at the end of the reporting period were RMB 182.023 billion, an increase of 11.37% compared to the end of the previous year[15] - The total liabilities of the company as of March 31, 2022, were RMB 107.64 billion, an increase from RMB 104.37 billion, marking a rise of 3.3%[25] - The total equity attributable to shareholders increased to RMB 64.52 billion from RMB 49.36 billion, reflecting a significant growth of 30.6%[26] - The company's inventory decreased to RMB 25.44 billion from RMB 27.10 billion, a decline of 6.1%[23] - Accounts receivable increased to RMB 63.47 billion, compared to RMB 58.11 billion, representing an increase of 9.5%[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 121,720, with the top ten shareholders holding significant stakes[19] - HKSCC NOMINEES LIMITED held 747,463,424 shares, representing 20.226% of the total shares[20] Other Financial Metrics - The company’s non-operating income and expenses totaled RMB 1.483 million, reflecting various adjustments in financial performance[16] - Investment income decreased by 87.92% due to reduced investment income from the disposal of subsidiaries during the reporting period[18] - Cash paid to employees and for employee benefits in Q1 2022 was 2,351,387,645.22, an increase from 2,246,036,982.65 in Q1 2021, reflecting higher personnel costs[32] - Cash paid for taxes in Q1 2022 was 2,107,415,362.61, compared to 2,021,368,619.52 in Q1 2021, indicating a rise in tax obligations[32]
上海医药(02607) - 2022 Q1 - 季度财报